<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056755</url>
  </required_header>
  <id_info>
    <org_study_id>CBYL719X2402</org_study_id>
    <nct_id>NCT03056755</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant</brief_title>
  <acronym>BYLieve</acronym>
  <official_title>A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+,
      HER2-negative aBC, with PIK3CA mutations, whose disease has progressed on or after CDK 4/6
      treatment with an aromatase inhibitor (AI) or fulvestrant
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2017</start_date>
  <completion_date type="Anticipated">February 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a phase II, multicenter, open-label, two-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in patients with HR+, HER2-negative aBC harboring PIK3CA mutation(s) in the tumor whose disease has progressed on or after CDK 4/6 inhibitor containing treatments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients who are alive without disease progression</measure>
    <time_frame>Date of first dose to approximately 6 months</time_frame>
    <description>Assess the percentage of patients without disease progression based on local investigator assessment per RECIST in cohort A and cohort B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) for each cohort</measure>
    <time_frame>date of first dose to up to approximately 25 months</time_frame>
    <description>PFS is defined as the time from the date of first dose of study medication to the date of the first documented progression or death due to any cause occurring in the study. PFS will be assessed based on local investigator's assessment according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) on next line treatment PFS2) for each cohort</measure>
    <time_frame>Date of first dose to date of first documented progression up to approximately 25 months</time_frame>
    <description>Progression free survival (PFS) on next line treatment (PFS2) is defined as time from the date of first dose of study medication to the date of first documented progression on next-line therapy or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants Overall response rate (ORR) for each cohort</measure>
    <time_frame>Date of first dose and up to approximately 25 months</time_frame>
    <description>ORR is defined as the percentage of participants with best overall response (BOR) of CR or partial response (PR), as per local investigator's assessment and according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinical benefit rate (CBR) for each cohort</measure>
    <time_frame>Date of first dose and up to approximately 25 months</time_frame>
    <description>CBR is defined as the percentage of participants with a best ORR of complete response (CR) or partial response (PR) or an overall lesion response of stable disease (SD) or Non-CR/ Non-PD lasting ≥ 24 weeks based on local investigator's assessment according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Date of first documented response to first documented progression or death up to approximately 25 months</time_frame>
    <description>Duration of Response is the time from the date of first documented response (confirmed CR or PR) to the date of first documented progression or death due to underlying cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>alpelisib + fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received any CDK 4/6 inhibitor plus aromatase inhibitor as treatment (immediately prior) will receive alpelisib + fulvestrant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alpelisib + letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received any CDK 4/6 inhibitor plus fulvestrant as treatment (immediately prior) will receive alpelisib + letrozole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpelisib</intervention_name>
    <description>300 mg; oral; once daily</description>
    <arm_group_label>alpelisib + fulvestrant</arm_group_label>
    <arm_group_label>alpelisib + letrozole</arm_group_label>
    <other_name>BYL719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>500 mg; intramuscular injection on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter</description>
    <arm_group_label>alpelisib + fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>2.5 mg; oral; once daily</description>
    <arm_group_label>alpelisib + letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is male or female 18 years or older

          -  Males or females with advanced (locoregionally recurrent or metatstatic) breast cancer
             not amenable to curative therapy

          -  In case of women, both premenopausal and postmenopausal patients are allowed to be
             included in study; menopausal status is relevant for the requirement of LHRH agonist
             (examples for use in this study include but not limited to goserelin, leuprolide or
             locally available treatment) to be used concomitantly with alpelisib and
             letrozole/fulvestrant

               1. Patient is postmenopausal woman defined as either:

                    -  Prior bilateral oophorectomy or

                    -  Age ≥60 or

                    -  Age &lt;60 and amenorrhea for 12 or more months (in the absence of
                       chemotherapy, tamoxifen, toremifene, or ovarian suppression) and FSH and/or
                       estradiol in the postmenopausal range per local normal range.

                  If patient is taking tamoxifen or toremifene and age &lt;60, then FSH and plasma
                  estradiol levels should be in post-menopausal range per local normal range.

                  Note: For women using therapy-induced amenorrhea other than ovarian radiation,
                  goserelin or leuprolide, etc., serial measurements of FSH and/or estradiol are
                  needed to ensure menopausal status

               2. Patient is premenopausal defined as either:

                    -  Patient had last menstrual period within the last 12 months or

                    -  If on tamoxifen or toremifene with in the past 14 days, plasma estradiol and
                       FSH must be in the premenopausal range per local normal range, or

                    -  In case of therapy induced amenorrhea, plasma estradiol and/or FSH must be
                       in the premenopausal range per local normal range

          -  Patient has histological and/or cytological confirmed ER+ and/or PgR+ aBC

          -  Patient has confirmed HER2-negative advanced breast cancer (aBC)

          -  Patient has a PIK3CA mutation confirmed by Novartis designated central lab or patient
             has a pathology report confirming PIK3CA mutant status by certified laboratory (using
             validated PI3KCA mutation assay) either from tissue or blood and must (mandatory) send
             tumor tissue to Novartis designated central lab for confirmation of mutational status

          -  Patient must have:

               -  Documented evidence of tumor progression on or after CDK 4/ 6 inhibitor
                  combination treatment; CDK 4/6 inhibitor must be the last treatment regimen prior
                  to study entry,

               -  No more than two (2) prior anti-cancer therapies for aBC

               -  Received no more than one prior regimen of chemotherapy in the metastatic setting

          -  Patient has either measurable disease per RECIST v1.1 or at least one predominantly
             lytic bone lesion must be present

          -  ECOG performance status ≤ 2

          -  Patient has fasting plasma glucose (FPG) ≤140 mg/dL (7.7 mmol/L) and glycosylated
             hemoglobin (HbA1c) ≤ 6.4% (both criteria have to be met)

          -  Patient has adequate bone marrow, coagulation, liver and renal function

        Exclusion Criteria:

          -  patient has known hypersensitivity to alpelisib, fulvestrant or letrozole

          -  Patient has received prior treatment with any PI3K inhibitors

          -  Patient with an established diagnosis of diabetes mellitus type I or uncontrolled type
             II

          -  Patient has a concurrent malignancy or malignancy within 3 years of study screening
             period, with the exception of adequately treated, basal or squamous cell carcinoma,
             non-melanoma skin cancer or curatively resected cervical cancer

          -  Patient has received radiotherapy ≤ 4 weeks or limited field radiation for palliation
             ≤ 2 weeks prior to enrollment, and who has not recovered to grade 1 or better from
             related side effects of such therapy

          -  History of acute pancreatitis within 1 year of screening or past medical history of
             pancreatitis

          -  Patients with central nervous system (CNS) involvement unless they meet ALL of the
             following criteria:

               -  At least 4 weeks from prior therapy completion (including radiation and/or
                  surgery) to starting the study treatment

               -  Clinically stable CNS tumor at the time of screening untreated or without
                  evidence of progressions for at least 4 weeks after treatment as determined by
                  clinical examination and brain imaging (MRI or CT) during screening period and
                  stable low dose of steroids for 2 weeks prior to initiating study treatment

          -  Patient with severe liver impairment (Child Pugh score B/C)

          -  Patient has impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of the study drugs

          -  Patient has documented pneumonitis which is active and requiring treatment

          -  Patient has a history of Stevens-Johnson-Syndrome (SJS) or Toxic Epidermal Necroloysis
             (TEN)

          -  Patient is concurrently using other anti-cancer therapy. All anti-cancer therapy must
             be discontinued prior to day one of study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Capilla</last_name>
      <phone>310-432-8900</phone>
      <email>fcapilla@bhcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Linea Chap</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maha Kadafour</last_name>
      <phone>415-885-3789</phone>
      <email>Maha.Kadafour@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Hope S Rugo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Research Collaboration, Inc</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deidre Carrillo</last_name>
      <phone>562-981-6101</phone>
      <email>deidre.carrillo@cancercollaboration.org</email>
    </contact>
    <investigator>
      <last_name>John Link</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa McConnell</last_name>
      <phone>410-332-1200</phone>
      <email>lmcconnell@mdmercy.com</email>
    </contact>
    <investigator>
      <last_name>David Andrew Riseberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kailey Prokop</last_name>
      <phone>406-238-6962</phone>
      <email>Kailey.Prokop@sclhs.net</email>
    </contact>
    <investigator>
      <last_name>Patrick Cobb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Alliance</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaylee Deutsch</last_name>
      <phone>505-925-0366</phone>
      <email>kdeutsch@nmcca.org</email>
    </contact>
    <investigator>
      <last_name>Ursa Brown-Glaberman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Corl</last_name>
      <phone>216-844-5176</phone>
      <email>Mary.Corl@Uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Paula Silverman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy &amp; Research Center at The University of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Rodriguez</last_name>
      <phone>210-450-1366</phone>
      <email>rodriguezk3@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Virginia Kaklamani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialists</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Walsh</last_name>
      <phone>253-396-5329</phone>
      <email>pwalsh@nwmsonline.com</email>
    </contact>
    <investigator>
      <last_name>Sibel Blau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Medical Center</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Adams</last_name>
      <phone>509-665-5800</phone>
      <email>crystal.adams@confluencehealth.org</email>
    </contact>
    <investigator>
      <last_name>Lindsay Overton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex 2</city>
        <state>Alpes Maritimes</state>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Cloud</city>
        <state>Hauts De Seine</state>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14169</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700160</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Delhi</city>
        <zip>110 085</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Castellon</city>
        <state>Comunidad Valenciana</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced breast cancer</keyword>
  <keyword>PIK3CA</keyword>
  <keyword>CDK 4/6 inhibitor</keyword>
  <keyword>fulvestrant</keyword>
  <keyword>letrozole</keyword>
  <keyword>HR+</keyword>
  <keyword>HER-negative</keyword>
  <keyword>post menopausal</keyword>
  <keyword>pre-menopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

